Healthcare Industry - Medical - Pharmaceutical - Biotech in San Francisco, United States

The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthal ..

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of ther ..

New this year we are offering a track for primary care providers and a track for athletic trainers and physical therapists. On days 1-2 we will present the top sports medicine injuries and conditions along with demonstrations of the relevant physical exams. Starting ..

With 128 TGF-B targeted therapies in the clinic and 68 in the preclinical stage, the TGF-B field is currently being rejuvenated by novel approaches in immuno-oncology, and cutting edge research in fibrosis, autoimmune diseases, and beyond. The TGF-B Targeted Drug ..

In 2024, age-related disease biotechs are set to shine, building on 2023's milestones such as Eli Lilly's partnership with BioAge to test muscle rejuvenation therapy and Chan Zuckerberg Biolabs tapping into immune cell engineering to eradicate age-related diseases. ..

This live course will include lectures, hands-on workshops, interactive question and answer sessions, that aim to provide an overview of pediatric musculoskeletal conditions and sports-related injuries that are commonly encountered by Primary Care Providers. This cou ..

Continuing in the spirit of innovation through collaboration, we are pleased to invite you to the second annual Personalizing Pediatric Cancer Care summit, cohosted by UCSF Benioff Children's Hospitals and Children's Hospital of Philadelphia. Join for an enlightening ..

Over the past decade, great strides have been made in our understanding of the pathobiology of pulmonary vascular disease, and from these findings new therapeutic options have emerged. It is increasingly clear that pulmonary vascular pathology is integral to a number ..

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, 2023 has set an exciting p ..

The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers, biochemists, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to ..

This course provides a comprehensive joint-by-joint review of common injuries and offers current Sports Medicine practices which apply to the care of all patients from the recreational participant to the specialized elite athlete. Highlights of this program include: ..

As the allogeneic cell therapy space continues to mature with over 150+ clinical trials currently underway, and landmark milestones achieved with the first FDA approvals for allogeneic cell products - all eyes are turning to the backbones of these cell therapies - th ..